AU2001288342A1 - Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders - Google Patents

Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Info

Publication number
AU2001288342A1
AU2001288342A1 AU2001288342A AU8834201A AU2001288342A1 AU 2001288342 A1 AU2001288342 A1 AU 2001288342A1 AU 2001288342 A AU2001288342 A AU 2001288342A AU 8834201 A AU8834201 A AU 8834201A AU 2001288342 A1 AU2001288342 A1 AU 2001288342A1
Authority
AU
Australia
Prior art keywords
rank ligand
treatment
monoclonal antibodies
mediated disorders
antibodies useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288342A
Inventor
Raymond W. Sweet
Mark A. Tornetta
Alemseged Truneh
Trevor A. Wattam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of AU2001288342A1 publication Critical patent/AU2001288342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
AU2001288342A 2000-08-21 2001-08-21 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders Abandoned AU2001288342A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22652400P 2000-08-21 2000-08-21
US60/226,524 2000-08-21
US23063900P 2000-09-07 2000-09-07
US60/230,639 2000-09-07
PCT/US2001/026161 WO2002015846A2 (en) 2000-08-21 2001-08-21 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Publications (1)

Publication Number Publication Date
AU2001288342A1 true AU2001288342A1 (en) 2002-03-04

Family

ID=26920612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288342A Abandoned AU2001288342A1 (en) 2000-08-21 2001-08-21 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Country Status (5)

Country Link
US (2) US20030211106A1 (en)
EP (1) EP1458411A2 (en)
JP (1) JP2004520011A (en)
AU (1) AU2001288342A1 (en)
WO (1) WO2002015846A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
PT2009025E (en) 1998-05-14 2011-09-19 Immunex Corp Method of inhibiting osteoclast activity
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
WO2002076507A2 (en) * 2001-03-23 2002-10-03 Genentech, Inc. Uses of opg ligand to modulate immune responses
EP1389233A4 (en) * 2001-05-18 2006-03-08 Smithkline Beecham Corp Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ES2907826T3 (en) 2001-06-26 2022-04-26 Amgen Inc Antibodies to OPGL
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
EP2020445B1 (en) * 2006-05-12 2013-01-02 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008078588A1 (en) * 2006-12-25 2008-07-03 National University Corporation Tokyo Medical And Dental University Pharmaceutical agent and method for treatment or prevention of articular cartilage deformation
AU2012201229B2 (en) * 2007-05-24 2014-10-16 Ablynx N.V. Amino acid sequences directed against Rank-L and polypeptides comprising the same for the treatment of bone diseases and disorders
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
CA2835340A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
CN105189551B (en) * 2013-03-14 2021-03-05 埃派斯进有限公司 anti-RANKL antibodies and methods of use thereof
EP3157950A4 (en) * 2014-06-20 2018-01-10 Stephen D. Gillies Influenza vaccines and methods of use thereof
CN105061604B (en) * 2015-08-19 2018-03-16 河南大学 SDR5 Fc fusion proteins mutant and its application
CN109890845B (en) * 2016-10-28 2022-07-01 伊莱利利公司 anti-RANKL antibodies and uses thereof
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IT1270866B (en) * 1993-03-10 1997-05-13 Eniricerche Spa RECOMBINANT VECTOR AND ITS USE FOR THE EXOCELLULAR PREPARATION OF ANTIBODIES IN THE FORM OF A SINGLE MOLECULE FROM BACILLUS SUBTILIS
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
HU221001B1 (en) * 1994-03-17 2002-07-29 Merck Patent Gmbh. Anti-egfr single-chain fvs, anti-egfr antibodies
WO1998028424A2 (en) * 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
WO1999029865A2 (en) * 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
ATE291628T1 (en) * 1998-09-15 2005-04-15 Pharmexa As METHOD FOR INHIBITING THE ACTIVITY OF OSTEOPROTEGERIN LIGANDS

Also Published As

Publication number Publication date
US20030211106A1 (en) 2003-11-13
JP2004520011A (en) 2004-07-08
WO2002015846A2 (en) 2002-02-28
US20040171117A1 (en) 2004-09-02
EP1458411A4 (en) 2004-09-22
EP1458411A2 (en) 2004-09-22
WO2002015846A3 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
AU2001266604A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
EP1482972A4 (en) Treatment of immunological disorders using anti-cd30 antibodies
IL212419A0 (en) Methods of administering anti-tnf antibodies
TWI365193B (en) Human antibodies that bind human il-12 and methods for producing
PL398596A1 (en) Preparation containing human antibodies for the treatment of disorders associated with TNF-α
IL214263A0 (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU5441000A (en) Human monoclonal antibody
AU2001239510A1 (en) Treatment of renal disorders
AU2002351374A8 (en) Antibodies to treat cancer
EP1389233A4 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2002309645A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
EP1380646A4 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
EP1278538A4 (en) Cd18-binding antibodies inhibit stenosis-related disorders
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2002320072A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
AU2001262611A1 (en) Single-chain variable fragment antibodies specific for the synaptic variant of acetylcholinesterase (ache-s), and their use in the diagnosis of progressive neuromuscular disorders
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
HUP0301798A3 (en) Treatment of eating disorders using carboxyalkylethers
WO2001092331A8 (en) Compositions and methods for the treatment of immune related diseases
AU2002316887A1 (en) Anti-ige antibody to treat ocular allergies
AU2001290553A1 (en) Method for using activated protein c for the treatment of coagulation-associated disorders